CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 2014—BioTheranostics introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provides personalized diagnostic information and therapeutic guidance for metastatic cancer patients.
The bioT3 product line includes CancerType ID, a proprietary molecular classifier for diagnosing tumor types and subtypes; CancerTarget ID, tumor-specific biomarker profiles for selecting on-label targeted therapies; and CancerTreatment ID, the newest product under bioT3, which combines next-generation sequencing and multi-platform predictive biomarkers to identify potential treatment options. The NGS technology uses targeted sequencing of a tumor’s DNA to simultaneously analyze 50 cancer-related genes for mutations that may be driving tumor growth.
BioTheranostics, 877-886-6739